Inventor · disambiguated record
Matthew J. Bernett
Also filed as: BERNETT MATTHEW · BERNETT MATTHEW J
102 granted patents·55 pending applications·1,080 citations·filing 2006–2025
99Inventor score
Top patents by PatentIndex Score
157 records- 0198US10793632B2Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptorsXENCOR INC·Filed 2017·Granted Oct 6, 2020·22 cites·5 claims
- 0298US10550185B2Bispecific heterodimeric fusion proteins containing IL-15-IL-15Rα Fc-fusion proteins and PD-1 antibody fragmentsXENCOR INC·Filed 2017·Granted Feb 4, 2020·29 cites·13 claims
- 0398US10501543B2IL15/IL15Rα heterodimeric Fc-fusion proteinsXENCOR INC·Filed 2017·Granted Dec 10, 2019·13 cites·6 claims
- 0498US10259887B2Heterodimeric antibodies that bind CD3 and tumor antigensXENCOR INC·Filed 2016·Granted Apr 16, 2019·25 cites·25 claims
- 0598US9856327B2Heterodimeric antibodies to CD3 X CD123XENCOR INC·Filed 2016·Granted Jan 2, 2018·72 cites·5 claims
- 0698US9701759B2Heterodimeric proteinsXENCOR INC·Filed 2014·Granted Jul 11, 2017·48 cites·8 claims
- 0798US9650446B2Heterodimeric proteinsXENCOR INC·Filed 2014·Granted May 16, 2017·44 cites·9 claims
- 0898US8637641B2Antibodies with modified isoelectric pointsDAHIYAT BASSIL I·Filed 2011·Granted Jan 28, 2014·140 cites·6 claims
- 0998US8329867B2CTLA4-Ig immunoadhesinsLAZAR GREGORY A·Filed 2011·Granted Dec 11, 2012·106 cites·13 claims
- 1097US11225528B2Heterodimeric antibodies that bind CD3 and tumor antigensXENCOR INC·Filed 2019·Granted Jan 18, 2022·11 cites·13 claims
- 1197US10787518B2Bispecific checkpoint inhibitor antibodiesXENCOR INC·Filed 2017·Granted Sep 29, 2020·15 cites·19 claims
- 1297US10526417B2Heterodimeric antibodies that bind CD3 and CD38XENCOR INC·Filed 2015·Granted Jan 7, 2020·27 cites·15 claims
- 1397US9605061B2Antibodies with modified isoelectric pointsXENCOR INC·Filed 2014·Granted Mar 28, 2017·43 cites·7 claims
- 1496US11358999B2IL-12 heterodimeric Fc-fusion proteinsXENCOR INC·Filed 2019·Granted Jun 14, 2022·12 cites·2 claims
- 1596US11254727B2CTLA4-Ig immunoadhesinsXENCOR INC·Filed 2021·Granted Feb 22, 2022·2 cites·4 claims
- 1696US10738133B2Heterodimeric proteinsXENCOR INC·Filed 2017·Granted Aug 11, 2020·9 cites·7 claims
- 1796US8551485B2Anti-CD40 antibodies and methods of inhibiting proliferation of CD40 expressing cellsBERNETT MATTHEW J·Filed 2009·Granted Oct 8, 2013·45 cites·27 claims
- 1896US8524867B2Optimized antibodies that target CD19BERNETT MATTHEW J·Filed 2007·Granted Sep 3, 2013·56 cites·32 claims
- 1995US12509495B2LAG-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and LAG-3 antigen binding domainsXENCOR INC·Filed 2023·Granted Dec 30, 2025·1 cites·5 claims
- 2095US11655277B2IL-12 heterodimeric Fc-fusion proteinsXENCOR INC·Filed 2022·Granted May 23, 2023·2 cites·1 claims
- 2195US11505595B2TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domainsXENCOR INC·Filed 2019·Granted Nov 22, 2022·9 cites·12 claims
- 2295US11053316B2Optimized antibody variable regionsXENCOR INC·Filed 2018·Granted Jul 6, 2021·7 cites·6 claims
- 2395US10981992B2Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptorsXENCOR INC·Filed 2018·Granted Apr 20, 2021·6 cites·6 claims
- 2495US10227411B2Modulation of T cells with bispecific antibodies and FC fusionsXENCOR INC·Filed 2016·Granted Mar 12, 2019·17 cites·7 claims
- 2595US9850320B2Heterodimeric antibodies to CD3 X CD20XENCOR INC·Filed 2016·Granted Dec 26, 2017·13 cites·5 claims
- 2695US9822186B2Bispecific antibodies that bind to CD38 and CD3XENCOR INC·Filed 2015·Granted Nov 21, 2017·17 cites·16 claims
- 2795US9221916B2Compositions and methods for treating IgE-mediated disordersXENCOR INC·Filed 2014·Granted Dec 29, 2015·12 cites·3 claims
- 2895US8629113B2CTLA4-Ig immunoadhesinsLAZAR GREGORY A·Filed 2012·Granted Jan 14, 2014·24 cites·23 claims
- 2995US8435517B2Compositions and methods for treating IgE-mediated disordersDESJARLAIS JOHN R·Filed 2009·Granted May 7, 2013·26 cites·8 claims
- 3095US8314213B2Human equivalent monoclonal antibodies engineered from nonhuman variable regionsBERNETT MATTHEW J·Filed 2009·Granted Nov 20, 2012·36 cites·4 claims
- 3194US12239688B2IL-15/IL-15RA heterodimeric Fc fusion proteins and uses thereofXENCOR INC·Filed 2021·Granted Mar 4, 2025·2 cites·20 claims
- 3294US11851466B2Targeted IL-12 heterodimeric Fc-fusion proteinsXENCOR INC·Filed 2020·Granted Dec 26, 2023·3 cites·16 claims
- 3394US11319355B2Engineered IL-2 Fc fusion proteinsXENCOR INC·Filed 2018·Granted May 3, 2022·5 cites·5 claims
- 3494US10131710B2Optimized antibody variable regionsXENCOR INC·Filed 2014·Granted Nov 20, 2018·15 cites·18 claims
- 3593US11634506B2Heterodimeric proteinsXENCOR INC·Filed 2020·Granted Apr 25, 2023·2 cites·9 claims
- 3693US11377477B2PD-1 targeted IL-15/IL-15RALPHA fc fusion proteins and uses in combination therapies thereofXENCOR INC·Filed 2019·Granted Jul 5, 2022·7 cites·13 claims
- 3793US10738132B2Heterodimeric proteinsXENCOR INC·Filed 2014·Granted Aug 11, 2020·9 cites·15 claims
- 3893US9617348B2Compositions and methods for treating IgE-mediated disordersXENCOR INC·Filed 2013·Granted Apr 11, 2017·11 cites·3 claims
- 3993US9540451B2Compositions and methods for treating IgE-mediated disordersXENCOR INC·Filed 2013·Granted Jan 10, 2017·8 cites·6 claims
- 4093US9266966B2Compositions and methods for treating IgE-mediated disordersXENCOR INC·Filed 2014·Granted Feb 23, 2016·8 cites·1 claims
- 4192US12398207B2Heterodimeric antibodies that bind CD3 and CLDN6XENCOR INC·Filed 2024·Granted Aug 26, 2025·1 cites·4 claims
- 4292US11945880B2Heterodimeric antibodies that bind CD3 and tumor antigensXENCOR INC·Filed 2021·Granted Apr 2, 2024·1 cites·13 claims
- 4392US11859011B2Heterodimeric antibodies that bind CD3 and tumor antigensXENCOR INC·Filed 2021·Granted Jan 2, 2024·1 cites·2 claims
- 4492US11618788B2Optimized antibodies that target CD19XENCOR INC·Filed 2020·Granted Apr 4, 2023·2 cites·16 claims
- 4592US11084863B2Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domainsXENCOR INC·Filed 2018·Granted Aug 10, 2021·7 cites·16 claims
- 4692US10155800B2CTLA4-Ig immunoadhesinsXENCOR INC·Filed 2016·Granted Dec 18, 2018·7 cites·9 claims
- 4791US11932675B2PD-1 targeted IL-15/IL-15Rα Fc fusion proteins with improved propertiesGENENTECH INC·Filed 2020·Granted Mar 19, 2024·2 cites·15 claims
- 4891US11584794B2Bispecific heterodimeric fusion proteins containing IL-15-IL-15Ralpha Fc-fusion proteins and immune checkpoint antibody fragmentsXENCOR INC·Filed 2019·Granted Feb 21, 2023·2 cites·9 claims
- 4991US10858417B2Heterodimeric proteinsXENCOR INC·Filed 2014·Granted Dec 8, 2020·7 cites·23 claims
- 5090US11618776B2Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15RA and NKG2D antigen binding domainsXENCOR INC·Filed 2019·Granted Apr 4, 2023·4 cites·7 claims
Showing the top 50 of 157 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Matthew J. Bernett files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →